Wegovy weight loss drug gets price cut in Israel—but only for lower doses
The reduction is welcome news for those just beginning treatment, as lower doses are typically prescribed in the early stages ...
Gulf Times5hOpinion
The half promise of weight-loss drugs
Groundbreaking weight-loss drugs like Ozempic and Wegovy have understandably generated a lot of excitement, bringing hope to ...
pharmaphorum11h
Novo Nordisk sheds billions in value on obesity data
Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...
pharmaphorum10h
Lilly grabs first-ever FDA nod for a sleep apnoea drug
Eli Lilly's Zepbound has become the first drug to be FDA-approved for obstructive sleep apnoea (OSA), a sleep-related ...
Is Merck the Next Big Weight-Loss Stock?
Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs ...
Daily Journal12h
Lilly stock caught up in wave of uncertainty
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...
FDA approves Zepbound for obstructive sleep apnea
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
The Oklahoman11h
OU football suffers blowout loss at LSU, awaits bowl destination | 5 takeaways
The Sooners' regular season ended with a thud, a 37-17 loss to LSU at Tiger Stadium. OU finished 6-6 overall and 2-6 in the SEC and now awaits its bowl fate. LSU quarterback Garrett Nussmeier had been ...